Page 105 - Read Online
P. 105
Dolan et al. Mini-invasive Surg 2020;4:40 I http://dx.doi.org/10.20517/2574-1225.2020.17 Page 9 of 10
lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation
Oncology Evidence-Based Clinical Practice Guideline. J Clin Oncol 2015;33:2100.
11. Butts C, Sociniski MA, Mitchel PL, Thatcher N, Havel L, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage
III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15:59-68.
12. Wu YL, Park K, Soo RA, Sun Y, Tyroller K, et al. INSPIRE: a phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian
patients with unresectable stage III non-small cell lung cancer. BMC Cancer 2011;11:430.
13. Antonia SJ, Villegas A, Daniel D, Vicente, D, Murakami S, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung
cancer. N Engl J Med 2017;377:1919-29.
14. Antonia SJ, Villegas A, Daniel D, Vicente, D, Murakami S, et al. Overall survival with durvalumab after chemoradiotherapy in stage III
NSCLC. N Engl J Med 2018;379:2342-50.
15. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, et al. A randomized trial comparing preoperative chemotherapy plus surgery
with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153-8.
16. Roth JA, Atkinson EN, Fossella F, Komaki R, Bernadette Ryan M, et al. Long-term follow-up of patients enrolled in a randomized trial
comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer
1998;21:1-6.
17. Albain KS, Suzanne Swann R, Rusch VW, Turrisi AT, Sheperd FA, et al. Radiotherapy plus chemotherapy with or without surgical
resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379.
18. van Meerbeeck JP, Kramer GWPM, Van Schil PEY, Legrand C, Smit EF, et al. Randomized controlled trial of resection versus
radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007;99.
19. Eberhardt WE, Pöttgen C, Gauler TC, Friedel G, Veit S, et al. Phase III study of surgery versus definitive concurrent chemoradiotherapy
boost in patients with resectable stage IIIA(N2) and selected IIIB non-small-cell lung cancer after induction chemotherapy and concurrent
chemoradiotherapy (ESPATUE). J Clin Oncol 2015;33:4194.
20. Zhu J, Li R, Tiselius E, Roudi R, Teghararian O, et al. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell
lung cancer treated with surgery or radiotherapy with curative intent. Cochrane Database Syst Rev 2017;12:CD011300.
21. Bott MJ, Cools-Lartigue J, Tan KS, Dycoco J, Bains MS, et al. Safety and feasibility of lung resection after immunotherapy for metastatic
or unresectable tumors. Ann Thorac Surg 2018;106:178-83.
22. Chaft JE, Forde PM, Smith KN, Anagnostou V, Cottrell T, et al. Neoadjuvant nivolumab in early-stage, resectable non-small cell lung
cancers. J Clin Onc 2017:15_suppl;8508.
23. Forde P, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med
2018;378:1976-86.
24. Vyfhuis MAL, Bhooshan N, Burrows WM, Turner M, Suthralingam M, et al. Oncological outcomes from trimodality therapy receiving
definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung
cancer. Adv Radiat Oncol 2017;2:259-69.
25. McElnay PJ, Choong A, Jordan E, Song F, Lim E. Outcome of surgery versus radiotherapy after induction treatment in patients with N2
disease: systematic review and meta-analysis of randomised trials. Thorax 2015;70:764-8.
26. Pless M, Stupp R, Ris HR, Stahel RA, Weder W, et al. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3
randomised trial. Lancet 2015;386:1049.
27. Pisters KM, Evans WK, Azzoli CG, Kris MG, Smith CA. Cancer care ontario and american society of clinical oncology adjuvant
chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 2007;25:5506.
28. Douillard JY, Rosell R, Delena M, Legroumellec A, Torres A, et al. ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus
observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): final results after 70-month
median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association. J Clin Onc 2005:16_suppl:7013.
29. Wang EH, Corso CD, Rutter CE, Park HS, Chen AB, et al. Postoperative radiation therapy is associated with improved overall survival in
incompletely resected stage II and III non-small-cell lung cancer. J Clin Oncol 2015;33:2727.
30. Burdett S, Rydzewska L, Tierney J, Fisher D, Parkar MKB, et al. Postoperative radiotherapy for non-small cell lung cancer. Cochrane
Database Syst Rev 2016;9:CD002142.
31. Francis S, Orton A, Stoddard G, Tao R, Hitchcock YJ, et al. Sequencing of postoperative radiotherapy and chemotherapy for locally
advanced or incompletely resected non-small-cell lung cancer. J Clin Oncol 2018;36:333.
32. Abbas AE. Surgical management of lung cancer: history, evolution, and modern advances. Curr Onc Rep 2018;20:98.
33. Huang J, Xu X, Chen H, Yin W, Shao W, et al. Feasibility of complete video-assisted thoracoscopic surgery following neoadjuvant
therapy for locally advanced non-small cell lung cancer. J Thorac Dis 2013;5: S267-73.
34. Park BJ, Yang HX, Woo KM, Sima CS. Minimally invasive (robotic assisted thoracic surgery and video-assisted thoracic surgery)
lobectomy for the treatment of locally advanced non-small cell lung cancer. J Thorac Dis 2016;8:S406-13.
35. Veronesi G, Park B, Cerfolio R, Dylewski M, Toker A, et al. Robotic resection of stage III lung cancer: an international retrospective
study. Euro J of Cardiothorac Surg 2018;54:912-9.
36. Gonfiotti A, Bongiolatti S, Bertolaccini L, Viggiano D, Solli P, et al. Thoracoscopic lobectomy for locally advanced-stage non-small cell
lung cancer is a feasible and safe approach: analysis from multi-institutional nation database. J Vis Surg 2017;3:160.
37. Tian Z, Sui X, Yang F, Wang J. Is video-assisted thoracoscopy a sufficient approach for mediastinal lymph node dissection to treat lung
cancer after neoadjuvant therapy? Thorac Cancer 2019;10:782-90.
38. Jaklitsch MT, Gu L, Demmy T, Harpole DH, D’Amico TA, et al. Prospective phase II trial of pre-resection thoracoscopic mediastinal